Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer

Not Applicable

• Conditions: Gastric Cancer
• Interventions: Procedure: Laparoscopic D2 lymphadenectomy; Procedure: Laparoscopic D2 lymphadenectomy plus CME

• Registration Number: NCT01978444
• Lead Sponsor: Huazhong University of Science and Technology

Brief Summary

Radical gastrectomy for gastric cancer with D2 lymph node dissection has been widely applied in advanced gastric cancer. However,for most patients,tumor local-regional recurrence has been proven unavoidable.

Recently, many clinical studies have proved that some cancer cells and cancer nodes exist in the mesogastrium which can be hardly removed by conventional radical gastrectomy with D2 lymphadenectomy. It is suggested that Complete mesogastrium excision (CME) is imperative and should be added to D2 lymphadenectomy in order to reduce the risk of local recurrence.

Thus, the comparison of short-term and long-term outcome between laparoscopic D2 lymphadenectomy plus complete mesogastrium excision and conventional laparoscopic D2 lymphadenectomy for locally advanced gastric cancer based on a well designed randomized controlled trial is needed.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-10-31
• Study First Submitted QC: 2013-10-31
• Study First Posted: 2013-11-07
• Study Start: 2014-09
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-09
• Last Update Posted: 2020-04-10
• Primary Completion: 2021-09
• Study Completion: 2023-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 169

Inclusion Criteria

Age from over 18 to under 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N0-3, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual Seventh Edition Expected curative resection through gastrectomy with D2 lymphadenectomy Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale ASA (American Society of Anesthesiology) score class I, II, or III Informed consent obtained from patients or their appointed agent

Exclusion Criteria

Patients treated with neoadjuvant chemotherapy or radiation therapy; Patients with history of upper abdominal surgery; History with other severe comorbidities and cannot tolerate laparoscopic surgery, such as severe heart and lung diseases, heart function below clinical stage 2, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc; Patients suffering from malignant diseases before the study or with other gastric malignant diseases, such as lymphoma and stromal tumors, etc.; Pregnant woman and woman during lactation; Patients with mental sickness; The patient compliance is bad or the researcher expect there will not be good patient compliance;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
laparoscopic D2 lymphadenectomy	Laparoscopic D2 lymphadenectomy	Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
laparoscopic D2 lymphadenectomy plus CME	Laparoscopic D2 lymphadenectomy plus CME	Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.

Primary Outcome Measures

Name	Time	Method
3-year disease free survival	36 months	3-years disease-free survival of the enrolled patients

Secondary Outcome Measures

Name	Time	Method
Postoperative recovery course	10 days	Time to first ambulation, flatus, liquid diet, soft diet, and duration of hospital stay. The amount of abdominal drainage and blood transfusion are also recorded.
Morbidity and mortality	30 days; 36 months	The early postoperative complication and mortality are defined as the event observed within 30 days after surgery, while the time frame for late complication is the period from postoperative day 31th to the end of month 36th.; * 3-year overall survival rate \[ Time Frame: 36 months \] \[ Designated as safety issue: No \]; * 3-year recurrence pattern \[ Time Frame: 36 months \] \[ Designated as safety issue: No \]; Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.
3-year overall survival	36 months	3-years overall survival of the enrolled patients

Trial Locations

Locations (1)

Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China